Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-20
    E.g., 2018-02-20

Articles

13798 items
9:02 AM, Feb 06, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest promoting IGFBP3 expression could help treat MYCN-driven neuroblastoma. In five MYCN-driven neuroblastoma cell lines, IGFBP3 encoded by a plasmid vector decreased viability compared with GFP. In a...
9:02 AM, Feb 06, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest IGF-2 could help treat autism. In a mouse model of autism, a single subcutaneous 30 μg/kg dose of IGF-2 decreased social interaction deficits, long-term non-aversive and aversive memory deficits and stereotyped...
7:02 PM, Feb 01, 2018  |  BC Innovations | Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
6:57 PM, Feb 01, 2018  |  BC Innovations | Tools & Techniques

Cutting a new path

As gene editing starts to make headway, its first indications are informed by the path laid by gene therapies and other nucleic acid modalities. But drug developers think editing is poised to move far beyond...
5:44 PM, Feb 01, 2018  |  BC Innovations | Translation in Brief

Ubiquitin choke point

Takeda has shown its first-in-class UBA1 inhibitor could safely treat cancer by blocking a protein on which virtually all cells depend for ubiquitin-mediated protein degradation, upending conventional wisdom about how to disrupt the pathway that...
5:12 PM, Feb 01, 2018  |  BC Innovations | Translation in Brief

Untangling MS

Multiple sclerosis researchers have typically sought to dial down inflammation and reduce disease metrics that encompass a wide range of disabilities. A UCLA team is bucking those trends by identifying disease-modifying targets in specific brain...
3:35 PM, Feb 01, 2018  |  BC Innovations | Translation in Brief

Cloning closer to home

Chinese Academy of Sciences researchers showed epigenetic modification is key for successful cloning of cynomolgus monkeys, overcoming the technical hurdles that have stalled the generation of live non-human primates despite success in 23 other mammalian...
12:01 PM, Feb 01, 2018  |  BC Innovations | Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other molecule...
8:47 AM, Feb 01, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest agonizing ABCA1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a tool compound ABCA1 agonist increased walking ability and rotarod...
8:47 AM, Feb 01, 2018  |  BC Innovations | Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy An engineered Cas9 mutant could be used for CRISPR-based gene editing with fewer off-target effects than standard Cas9. The engineered enzyme was generated by screening a library of Cas9 mutants in a yeast-based...

Pages